1. Home
  2. XWIN vs ANL Comparison

XWIN vs ANL Comparison

Compare XWIN & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

XWIN

XMAX Inc.

N/A

Current Price

$7.16

Market Cap

259.3M

ML Signal

N/A

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$6.46

Market Cap

293.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
XWIN
ANL
Founded
2003
2004
Country
United States
Cayman Islands
Employees
27
N/A
Industry
Home Furnishings
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
259.3M
293.4M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
XWIN
ANL
Price
$7.16
$6.46
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$16.00
AVG Volume (30 Days)
980.9K
181.7K
Earning Date
05-14-2026
04-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.20
$0.88
52 Week High
$7.42
$12.09

Technical Indicators

Market Signals
Indicator
XWIN
ANL
Relative Strength Index (RSI) 79.52 36.85
Support Level $5.58 $1.36
Resistance Level N/A $9.98
Average True Range (ATR) 0.20 0.76
MACD 0.10 -0.24
Stochastic Oscillator 81.27 5.56

Price Performance

Historical Comparison
XWIN
ANL

About XWIN XMAX Inc.

XMax Inc is a designer and lifestyle furniture company. It distributes and retails contemporary styled residential and commercial furniture. The firms marketing and sales platform offers retail as well as online selection and purchase fulfillment internationally. The company also sells managed a variety of bedding foundation components. Its collection of lifestyle furniture brands includes Diamond Sofa. The firm's products are made in the United States and Asia. Its customers mainly comprise distributors and retailers having specific geographic coverages that deploy middle to high-end private label home furnishings. The company operates in one business and industry segment: the design and sale of furniture.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.

Share on Social Networks: